Home › Drievoudig negatieve borstkanker › Tennessee › Nashville
Drievoudig negatieve borstkanker klinische studies in Nashville, TN
28 studies voor Drievoudig negatieve borstkanker zoeken deelnemers op locaties in en rond Nashville (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruterenFase 1
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruterenFase 1/2
- Sarah Cannon Research Institute, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekruterenFase 1
- Sarah Cannon Research Institute (SCRI), Nashville
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
RekruterenFase 1
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RekruterenFase 1/2
- SCRI Oncology Partners, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruterenObservatieonderzoek
- Vanderbilt University Medical Center, Nashville
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruterenFase 3
- SCRI Oncology Partners ( Site 7004), Nashville
- Tennessee Oncology ( Site 0018), Nashville
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekruterenFase 3
- One Oncology - Tennessee Oncology ( Site 0098), Nashville
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0111), Nashville
- en nog 1
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruterenFase 3
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruterenFase 1
- Sarah Cannon - Tennessee Oncology, Nashville
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RekruterenObservatieonderzoek
- Nashville General, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruterenFase 1
- Normunity Investigational Site, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Vanderbilt University Medical Center, Nashville
SMP-3124LP in Adults With Advanced Solid Tumors
RekruterenFase 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruterenFase 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RekruterenFase 1
- Tennessee Oncology, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruterenFase 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
RekruterenFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
Study of XB010 in Subjects With Solid Tumors
RekruterenFase 1
- SCRI Oncology Partners, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RekruterenFase 1
- SCRI Oncology Partners, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Rekruteren
- Vanderbilt-Ingram Cancer Center, Nashville
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RekruterenFase 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
RekruterenFase 1/2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
RekruterenFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RekruterenFase 2
- SCRI Oncology Partners, Nashville
Drievoudig negatieve borstkanker studies in andere steden
- Houston, TX42 studies
- New York City, NY31 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
- Grand Rapids, MI15 studies
Andere studies in Nashville
- Niet-kleincellige longkanker97 studies
- Borstkanker81 studies
- Metastatische kanker70 studies
- Colorectale kanker69 studies
- Kanker (alle vormen)65 studies
- Eierstokkanker49 studies
- Prostaatkanker43 studies
- Longkanker40 studies
- Plaveiselcelcarcinoom van hoofd en hals39 studies
- Aldermeesklierkanker39 studies
- Endometriumkanker38 studies
- Melanoom33 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.